Global Cancer Tissue Diagnostics Market: Segment Snapshot and Table of Content 2016 - 2026

FMI’s report titled “Cancer Tissue Diagnostics Market: Global Industry Analysis and Opportunity Assessment 2016–2026” also cites that North America represents the most lucrative market for cancer tissue diagnostics, followed by Europe and APAC. In 2016, North America accounted for more than 36% share of the global market. The cancer tissue diagnostics market in this region is expected to reach a valuation of US$ 4,017.7 Mn towards the end of 2026. This growth is primarily attributed to factors such as the constantly extending list of cancer biomarkers and the presence of advance healthcare infrastructures in the region. Meanwhile, Asia Pacific excluding Japan (APEJ) is also anticipated to witness a strong growth of its market over the next couple of years. By 2026-end, the region’s market is expected to reach US$ 1,107.7 Mn in terms of revenue.

A recent study conducted by Future Market Insights (FMI) reveals that the global cancer tissue diagnostics market, which is currently valued at over US$ 4345 Mn, will expand at a healthy CAGR of 8.3% during the forecast period (2016-2026).

Segmentation highlights

Global Cancer Tissue Diagnostics Market Attractiveness Analysis by Region, 2016 – 2026

North America dominated the global cancer tissue diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America accounted for 36.5% value share in 2016 and is projected to account for more than 40% share by 2026 end. In terms of value, APEJ is expected to register a CAGR of 8.0% during the forecast period. Despite a low value CAGR of 5.7%, the MEA cancer tissue diagnostics market is projected to grow 1.9X over 2016–2026.

Report Overview @ https://www.futuremarketinsights.com/reports/cancer-tissue-diagnostics-market

Constantly growing list of cancer biomarkers boosting the cancer tissue diagnostics market

Sheer number of biomarkers that can be utilised for early cancer detection from blood or plasma samples are constantly increasing, which is expected to bring new cancer biomarker tests in the market in the near future. For instance, researchers at the University of Sheffield have recently identified over 700 new blood biomarkers that can be used for early cancer detection. As per OECD statistics, the global biomarkers market for companion diagnostics was valued at about US$ 8.4 Bn in 2016. The growth in companion diagnostics is indicative of acceptance of biomarkers in healthcare systems and may offer attractive incentives for biomarkers business development.

Advanced diagnostics at reduced costs aiding the global cancer tissue diagnostics market

After the completion of the human genome project in 2003, cost of assembling one genome has reduced tremendously and also cut down the time of analysis with development of highly advanced sequencing equipment. For instance, in January 2014, Illumina Inc. launched HighSeq X Ten Sequencer, which cut down the cost of genome sequencing to as low as US$ 1,000 including reagents cost and sample preparation equipment depreciation cost. Further advancements may continue to push down the cost for less than the cost of an X-ray, which would enhance the accessibility of this technology and thus drive the growth of the market. This also facilitates the use of highly advanced technologies by smaller research and clinical laboratories that possess less technical expertise and low resources.

Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-4191

Summary of Table of Content
1. Executive Summary
2. Cancer Tissue Diagnostics Introduction
3. Cancer Tissue Diagnostics Analysis Scenario
4. Cancer Tissue Diagnostics Analysis Scenario
5. Global Cancer Tissue Diagnostics Analysis and Forecast, By Test Type
6. Global Cancer Tissue Diagnostics Analysis and Forecast, By Region
7. North America Cancer Tissue Diagnostics Analysis and Forecast
8. Latin America Cancer Tissue Diagnostics Analysis and Forecast
9. Western Europe Cancer Tissue Diagnostics Analysis and Forecast
10. Eastern Europe Cancer Tissue Diagnostics Analysis and Forecast
11. Asia Pacific Excl. Japan (APEJ) Cancer Tissue Diagnostics Analysis and Forecast
12. Japan Cancer Tissue Diagnostics Analysis and Forecast
13. Competition Landscape
14. Assumptions and Acronyms Used
15. Research Methodology

Request to Browse Full Table of Content, figure and Tables @ https://www.futuremarketinsights.com/reports/cancer-tissue-diagnostics-market/toc

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com

This release was published on openPR.